Strides Shasun launches Ranitidine Tablets in US markets

Strides Shasun Limited announced that it is going to launch Ranitidine Tablets USP, 150 mg in the US markets. The company is already a major performer in the US Ranitidine Rx market and enjoying around 32 per cent market share.

Ranitidine tablets are used to treat digestive ulcers of the stomach and intestines and gastroesophageal reflux and heartburn related to indigestion. Company expects that this fresh introduction of Ranitidine Tablets will help to support company’s Ranitidine franchise.

Company’s new product pipeline is strong and sustained R&D investment of Rs. 42 crore in Q3FY18. The company is on track to deliver 15-20 new product applications during the year, of which 12 have already been filed.

Strides Shasun is a vertically integrated global pharmaceutical company operating in two business verticals: Regulated markets and Emerging markets. It has worldwide manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 USFDA approved facilities and 2 facilities for the emerging markets.

Cheering the news, the stock jumped by almost 3 per cent and touched an intra-day high of Rs. 715.90, on BSE on Monday.